Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

The International Headache Society recently issued a position paper that upgraded the standards for migraine prevention, ...

Management now expects first-quarter revenues ... higher than the initial guidance of $126.9 million to $130.9 million. This strong revenue growth is likely to be driven by the introduction ...

The experience of the Consensus Group suggests that intermittent treatment should be preferred to continuous therapy. However, the lack of data supporting this impression is recognised.

SAN DIEGO — The use of NSAIDs may be an effective way to reduce postoperative stiffness and manipulation under anesthesia procedures following total knee arthroplasty, according to results ...